Zenyaku Kogyo Co. Ltd.

5 articles about Zenyaku Kogyo Co. Ltd.

• ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan

  6/22/2023

  ASLAN Pharmaceuticals and Zenyaku Kogyo Co., Ltd. (“Zenyaku”), a subsidiary of privately held Zenyaku Holdings Co., Ltd. (“Zenyaku Holdings”), today announced a strategic licensing agreement granting Zenyaku exclusive rights to develop and commercialize eblasakimab in atopic dermatitis (AD) and all other indications in Japan.

• Anthera Shares Slump as Zenyaku Kogyo Backs Out of Blisibimod Deal

  9/15/2015

• Anthera Pharmaceuticals, Inc. Licenses Japan Rights For Blisibimod To Zenyaku Kogyo

  12/15/2014

• Zenyaku Kogyo Obtains Exclusive License in Japan to Theraclone Sciences, Inc.'s Influenza Monoclonal Antibody Program

  3/22/2010

• Theraclone Sciences, Inc. and Zenyaku Kogyo Announce Influenza Antibody Alliance

  10/5/2009